Overactive Bladder Treatment Market - Top Companies and Manufacturers

In the News

• Astellas Pharma, Inc. reported that the U.S Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and frequency. 
• AbbVie Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BOTOX the only exclusive neurotoxic, which provides a novel therapeutic alternative for the treatment of neurogenic detrusor overactivity in pediatric patients who are not well controlled by anticholinergic drugs. Further, BOTOX is one of the most extensively researched drugs in the world which is injected into muscles and also used to treat overactive bladder symptoms such as a strong need to urinate with urge urinary incontinence, urgency, and urinating frequently.